Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Connection

Jennifer Barker to Humans

This is a "connection" page, showing publications Jennifer Barker has written about Humans.

 
Connection Strength
 
 
 
0.236
 
  1. Barker JM. A Window into Understanding the Lasting Impact of the Nutritional Milieu in Adolescents: Anorexia Nervosa as a Model. J Clin Endocrinol Metab. 2021 03 25; 106(4):e1905-e1906.
    View in: PubMed
    Score: 0.021
  2. Barker JM, Bajaj L. Hypo and Hyper: Common Pediatric Endocrine and Metabolic Emergencies. Adv Pediatr. 2015 Aug; 62(1):257-82.
    View in: PubMed
    Score: 0.014
  3. Chan CL, McFann K, Taylor L, Wright D, Zeitler PS, Barker JM. Congenital adrenal hyperplasia and the second newborn screen. J Pediatr. 2013 Jul; 163(1):109-13.e1.
    View in: PubMed
    Score: 0.012
  4. Baker PR, Nanduri P, Gottlieb PA, Yu L, Klingensmith GJ, Eisenbarth GS, Barker JM. Predicting the onset of Addison's disease: ACTH, renin, cortisol and 21-hydroxylase autoantibodies. Clin Endocrinol (Oxf). 2012 May; 76(5):617-24.
    View in: PubMed
    Score: 0.011
  5. Barker JM. Compounding risk for hypoglycemia: type 1 diabetes and Addison's disease. Diabetes Technol Ther. 2012 May; 14(5):383-5.
    View in: PubMed
    Score: 0.011
  6. Triolo TM, Armstrong TK, McFann K, Yu L, Rewers MJ, Klingensmith GJ, Eisenbarth GS, Barker JM. Additional autoimmune disease found in 33% of patients at type 1 diabetes onset. Diabetes Care. 2011 May; 34(5):1211-3.
    View in: PubMed
    Score: 0.010
  7. Triolo TM, Baschal EE, Armstrong TK, Toews CS, Fain PR, Rewers MJ, Yu L, Miao D, Eisenbarth GS, Gottlieb PA, Barker JM. Homozygosity of the polymorphism MICA5.1 identifies extreme risk of progression to overt adrenal insufficiency among 21-hydroxylase antibody-positive patients with type 1 diabetes. J Clin Endocrinol Metab. 2009 Nov; 94(11):4517-23.
    View in: PubMed
    Score: 0.009
  8. Barker JM, Triolo TM, Aly TA, Baschal EE, Babu SR, Kretowski A, Rewers MJ, Eisenbarth GS. Two single nucleotide polymorphisms identify the highest-risk diabetes HLA genotype: potential for rapid screening. Diabetes. 2008 Nov; 57(11):3152-5.
    View in: PubMed
    Score: 0.009
  9. Taplin CE, Barker JM. Autoantibodies in type 1 diabetes. Autoimmunity. 2008 Feb; 41(1):11-8.
    View in: PubMed
    Score: 0.008
  10. Barker JM, Liu E. Celiac disease: pathophysiology, clinical manifestations, and associated autoimmune conditions. Adv Pediatr. 2008; 55:349-65.
    View in: PubMed
    Score: 0.008
  11. Taplin CE, Barker JM. Natural evolution, prediction, and prevention of type 1 diabetes in youth. Endocr Res. 2008; 33(1-2):17-33.
    View in: PubMed
    Score: 0.008
  12. Barker JM, McFann KK, Orban T. Effect of oral insulin on insulin autoantibody levels in the Diabetes Prevention Trial Type 1 oral insulin study. Diabetologia. 2007 Aug; 50(8):1603-6.
    View in: PubMed
    Score: 0.008
  13. Barker JM, Eisenbarth GS. Primary prevention of type 1A diabetes: are we there yet? Pediatr Diabetes. 2007 Jun; 8(3):115-6.
    View in: PubMed
    Score: 0.008
  14. Barker JM, McFann K, Harrison LC, Fourlanos S, Krischer J, Cuthbertson D, Chase HP, Eisenbarth GS. Pre-type 1 diabetes dysmetabolism: maximal sensitivity achieved with both oral and intravenous glucose tolerance testing. J Pediatr. 2007 Jan; 150(1):31-36.e6.
    View in: PubMed
    Score: 0.008
  15. Kishiyama CM, Chase HP, Barker JM. Prevention strategies for type 1 diabetes. Rev Endocr Metab Disord. 2006 Sep; 7(3):215-24.
    View in: PubMed
    Score: 0.007
  16. Barker JM. Clinical review: Type 1 diabetes-associated autoimmunity: natural history, genetic associations, and screening. J Clin Endocrinol Metab. 2006 Apr; 91(4):1210-7.
    View in: PubMed
    Score: 0.007
  17. Barker JM, Yu J, Yu L, Wang J, Miao D, Bao F, Hoffenberg E, Nelson JC, Gottlieb PA, Rewers M, Eisenbarth GS. Autoantibody "subspecificity" in type 1 diabetes: risk for organ-specific autoimmunity clusters in distinct groups. Diabetes Care. 2005 Apr; 28(4):850-5.
    View in: PubMed
    Score: 0.007
  18. Barker JM. Polyendocrine autoimmunity. Curr Diab Rep. 2005 Apr; 5(2):84-90.
    View in: PubMed
    Score: 0.007
  19. Barker JM, Ide A, Hostetler C, Yu L, Miao D, Fain PR, Eisenbarth GS, Gottlieb PA. Endocrine and immunogenetic testing in individuals with type 1 diabetes and 21-hydroxylase autoantibodies: Addison's disease in a high-risk population. J Clin Endocrinol Metab. 2005 Jan; 90(1):128-34.
    View in: PubMed
    Score: 0.007
  20. Barker JM, Barriga KJ, Yu L, Miao D, Erlich HA, Norris JM, Eisenbarth GS, Rewers M. Prediction of autoantibody positivity and progression to type 1 diabetes: Diabetes Autoimmunity Study in the Young (DAISY). J Clin Endocrinol Metab. 2004 Aug; 89(8):3896-902.
    View in: PubMed
    Score: 0.006
  21. Barker JM, Goehrig SH, Barriga K, Hoffman M, Slover R, Eisenbarth GS, Norris JM, Klingensmith GJ, Rewers M. Clinical characteristics of children diagnosed with type 1 diabetes through intensive screening and follow-up. Diabetes Care. 2004 Jun; 27(6):1399-404.
    View in: PubMed
    Score: 0.006
  22. Dyess NF, Weikel BW, Barker JM, Garrington TP, Parker TA. Parental leave during pediatric fellowship training: A national survey. PLoS One. 2022; 17(12):e0279447.
    View in: PubMed
    Score: 0.006
  23. Singh I, Noel G, Barker JM, Chatfield KC, Furniss A, Khanna AD, Nokoff NJ, Patel S, Pyle L, Nahata L, Cole FS, Ikomi C, Bamba V, Fechner PY, Davis SM. Hepatic abnormalities in youth with Turner syndrome. Liver Int. 2022 10; 42(10):2237-2246.
    View in: PubMed
    Score: 0.006
  24. Barker J, Travers S. Case report: an 11-year-old girl with tetany. Curr Opin Pediatr. 2002 Jun; 14(3):338-42.
    View in: PubMed
    Score: 0.006
  25. Guzewicz L, Howell S, Crerand CE, Umbaugh H, Nokoff NJ, Barker J, Davis SM. Clinical phenotype and management of individuals with mosaic monosomy X with Y chromosome material stratified by genital phenotype. Am J Med Genet A. 2021 05; 185(5):1437-1447.
    View in: PubMed
    Score: 0.005
  26. Popler J, Alimohammadi M, K?mpe O, Dalin F, Dishop MK, Barker JM, Moriarty-Kelsey M, Soep JB, Deterding RR. Autoimmune polyendocrine syndrome type 1: Utility of KCNRG autoantibodies as a marker of active pulmonary disease and successful treatment with rituximab. Pediatr Pulmonol. 2012 Jan; 47(1):84-7.
    View in: PubMed
    Score: 0.003
  27. Baker PR, Baschal EE, Fain PR, Nanduri P, Triolo TM, Siebert JC, Armstrong TK, Babu SR, Rewers MJ, Gottlieb PA, Barker JM, Eisenbarth GS. Dominant suppression of Addison's disease associated with HLA-B15. J Clin Endocrinol Metab. 2011 Jul; 96(7):2154-62.
    View in: PubMed
    Score: 0.003
  28. Baker PR, Baschal EE, Fain PR, Triolo TM, Nanduri P, Siebert JC, Armstrong TK, Babu SR, Rewers MJ, Gottlieb PA, Barker JM, Eisenbarth GS. Haplotype analysis discriminates genetic risk for DR3-associated endocrine autoimmunity and helps define extreme risk for Addison's disease. J Clin Endocrinol Metab. 2010 Oct; 95(10):E263-70.
    View in: PubMed
    Score: 0.002
  29. Babaya N, Yu L, Miao D, Wang J, Rewers M, Nakayama M, Liu E, Barker JM, Eisenbarth GS. Comparison of insulin autoantibody: polyethylene glycol and micro-IAA 1-day and 7-day assays. Diabetes Metab Res Rev. 2009 Oct; 25(7):665-70.
    View in: PubMed
    Score: 0.002
  30. Triolo TM, Chase HP, Barker JM. Diabetic subjects diagnosed through the Diabetes Prevention Trial-Type 1 (DPT-1) are often asymptomatic with normal A1C at diabetes onset. Diabetes Care. 2009 May; 32(5):769-73.
    View in: PubMed
    Score: 0.002
  31. Zhang L, Gianani R, Nakayama M, Liu E, Kobayashi M, Baschal E, Yu L, Babu S, Dawson A, Johnson K, Jahromi M, Aly T, Fain P, Barker J, Rewers M, Eisenbarth GS. Type 1 diabetes: chronic progressive autoimmune disease. Novartis Found Symp. 2008; 292:85-94; discussion 94-8, 122-9, 202-3.
    View in: PubMed
    Score: 0.002
  32. Zhang L, Barker JM, Babu S, Su M, Stenerson M, Cheng M, Shum A, Zamir E, Badolato R, Law A, Eisenbarth GS, Anderson MS. A robust immunoassay for anti-interferon autoantibodies that is highly specific for patients with autoimmune polyglandular syndrome type 1. Clin Immunol. 2007 Nov; 125(2):131-7.
    View in: PubMed
    Score: 0.002
  33. Aly TA, Ide A, Jahromi MM, Barker JM, Fernando MS, Babu SR, Yu L, Miao D, Erlich HA, Fain PR, Barriga KJ, Norris JM, Rewers MJ, Eisenbarth GS. Extreme genetic risk for type 1A diabetes. Proc Natl Acad Sci U S A. 2006 Sep 19; 103(38):14074-9.
    View in: PubMed
    Score: 0.002
  34. Aly TA, Ide A, Humphrey K, Barker JM, Steck A, Erlich HA, Yu L, Miao D, Redondo MJ, McFann K, Roberts CM, Babu SR, Norris JM, Eisenbarth GS, Rewers MJ. Genetic prediction of autoimmunity: initial oligogenic prediction of anti-islet autoimmunity amongst DR3/DR4-DQ8 relatives of patients with type 1A diabetes. J Autoimmun. 2005; 25 Suppl:40-5.
    View in: PubMed
    Score: 0.002
  35. Aly T, Devendra D, Barker J, Liu E, Yu L, Eisenbarth GS. Heterophile antibodies masquerade as interferon-alpha in subjects with new-onset type 1 diabetes. Diabetes Care. 2004 May; 27(5):1205-6.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)